APA

Hanfstein B., Shlyakhto V., Lauseker M., Hehlmann R., Saussele S., Dietz C., Erben P., Fabarius A., Proetel U., Schnittger S., Krause S. W., Schubert J., Einsele H., Hänel M., Dengler J., Falge C., Kanz L., Neubauer A., Kneba M., Stegelmann F., Pfreundschuh M., Waller C. F., Spiekermann K., Baerlocher G. M., Pfirrmann M., Hasford J., Hofmann W., Hochhaus A. & Müller M. C. (20141203). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. : Leukemia.

Chicago

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause S W, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller C F, Spiekermann K, Baerlocher G M, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A and Müller M C. 20141203. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. : Leukemia.

Harvard

Hanfstein B., Shlyakhto V., Lauseker M., Hehlmann R., Saussele S., Dietz C., Erben P., Fabarius A., Proetel U., Schnittger S., Krause S. W., Schubert J., Einsele H., Hänel M., Dengler J., Falge C., Kanz L., Neubauer A., Kneba M., Stegelmann F., Pfreundschuh M., Waller C. F., Spiekermann K., Baerlocher G. M., Pfirrmann M., Hasford J., Hofmann W., Hochhaus A. and Müller M. C. (20141203). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. : Leukemia.

MLA

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause S W, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller C F, Spiekermann K, Baerlocher G M, Pfirrmann M, Hasford J, Hofmann W-K, Hochhaus A and Müller M C. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. : Leukemia. 20141203.